<DOC>
	<DOCNO>NCT02284490</DOCNO>
	<brief_summary>This phase II trial study well pemetrexed disodium work treat patient Lung Adenocarcinoma With Brain Metastases</brief_summary>
	<brief_title>High-dose Pemetrexed Treat Lung Adenocarcinoma With Brain Metastases</brief_title>
	<detailed_description>- Determine 6-month progression-free survival rate patient Lung Adenocarcinoma With Brain Metastases treat pemetrexed disodium . - Determine time progression patient Lung Adenocarcinoma With Brain Metastases treat pemetrexed disodium . Secondary - Determine radiographic response patient Lung Adenocarcinoma With Brain Metastases treat pemetrexed disodium . - Determine time response patient treated drug . - Determine duration response patient treated drug . - Determine overall survival patient treated drug . - Collect safety data patient intracranial tumor treat drug . OUTLINE : Patients receive pemetrexed disodium IV 10 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm brain metastasis lung adenocarcinoma . Measurable ( great 1 cm diameter ) tumor CT scan MRI . ECOG ( Eastern Cooperative Oncology Group ) Performance status 01 . Measurable disease define bidimensionally measurable lesion clearly define margin CT scan MRI . Biopsy require radiographic imaging consistent brain metastasis . Must fail prior wholebrain radiotherapy . Patients leptomeningeal metastasis without brain metastasis eligible therapy ( may diagnose MRI cytology ) . Karnofsky performance score â‰¥ 60 WBC &gt; 3,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 10 mg/dL ( transfusion allow ) SGOT/SGPT &lt; 3.0 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Creatinine &lt; 1.5 mg/dL Creatinine clearance &gt; 45 mL/min Women childbearing potential sexually active male must commit use effective contraception study 3 month complete study treatment Women pregnant breastfeeding eligible study treatment Negative pregnancy test Able take steroid , vitamin B12 , folate No significant medical illness infection , investigator 's opinion , adequately controlled appropriate therapy would compromise patient 's ability tolerate therapy Symptomatic brain metastasis Have receive prior radiotherapy brain metastasis Unable unwilling take folic acid , vitamin B12 supplementation dexamethasone ( equivalent corticosteroid ) ; inability comply protocol study related procedure . A prior malignancy NSCLC , except carcinoma situ cervix nonmelanoma skin cancer , adequately treat low grade [ Gleason score &lt; 6 ] localize prostate cancer , unless prior malignancy diagnose definitively treat least 5 year previously subsequent evidence recurrence Serious concomitant systemic disorder ( example , active infection abnormal electrocardiogram ( ECG ) indicative cardiac disease ) , opinion investigator , would compromise safety patient his/her ability complete study . Inability discontinue administration aspirin dose &gt; 1.3g/day nonsteroidal antiinflammatory agent 2 day , day , 2 day dose pemetrexed ( 5 day prior longacting agent piroxicam ) . Presence fluid accumulation third space , e.g. , ascite pleural effusion , detect clinically ( physical examination ) , adequately control drainage procedure prior inclusion study . Peripheral neuropathy &gt; CTC Grade 2 Patient compliance geographic distance preclude adequate follow .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Brain Metastases</keyword>
</DOC>